Although substantial progress has been made towards improving
gender- and sex-specific ACS disease management and outcomes,
contemporary reports indicate a persistent knowledge gap with regard to
optimal risk-stratification and management in female ACS patients.
Prominent patient and system delays in women with AMI result
from limited awareness for the latent CVD risk in women, a lack of sexspecific
thresholds within clinical guidelines, and subsequent limited
performance of contemporary diagnostic approaches in women, all of
which are the result of a persistent underrepresentation of women in
cardiovascular studies